JIC
AMAG

Joel Isaacson & Co’s AMAG Pharmaceuticals AMAG Stock Holding History

Joel Isaacson & Co’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,000
Closed -$23K – 786
2016
Q1 		$23K Buy
+1,000
New +$23.7K 0.01% 467

Other funds holding AMAG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SIM
Stelliam Investment Management New York $404M AUM 5.1% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Joel Isaacson & Co's AMAG Position: Q2 2016 in Review

Joel Isaacson & Co sold out of AMAG Pharmaceuticals (AMAG) in Q2 2016, closing a stake of 1,000 shares — an estimated $23K sold.

Joel Isaacson & Co first reported a position in AMAG in Q1 2016 and held it in 1 quarter. The position peaked at $23K in Q1 2016. 165 funds tracked by Wall St. Rank hold AMAG as of Q2 2016.

  • Joel Isaacson & Co reported no remaining AMAG Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Joel Isaacson & Co sold 1,000 AMAG Pharmaceuticals shares in Q2 2016, an estimated $23K.
  • Joel Isaacson & Co first reported a position in AMAG Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Joel Isaacson & Co's AMAG Pharmaceuticals position peaked at $23K in Q1 2016.
  • 165 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q2 2016.

Based on Joel Isaacson & Co's 13F filing for Q2 2016, filed 22 Jul 2016.